胃蛋白酶原与胃泌素-17在胃癌前病变筛查中的价值(1)
摘要：目的 探討血清胃蛋白酶原Ⅰ、Ⅱ(PGⅠ、Ⅱ)与胃泌素-17(G-17)在胃癌前病变中的诊断价值。方法 回顾性分析2018年1月～10月我院收治的消化道患者98例，根据胃镜检查及病理结果分为胃溃疡组32例、萎缩性胃炎组21例、肠上皮化生组25例、低级别上皮内瘤变组20例，另选取同期我院检查的健康体检者30名作为对照组。应用ELISA法检测比较五组血清PGⅠ、PGⅡ、胃蛋白酶原比值PGR，(PGI/PGⅡ)、G-17水平。结果 与对照组比较，胃溃疡组PGⅠ、PGⅡ、G-17升高[(131.83±24.62)μg/L vs(95.29±23.47)μg/L]、[(15.31±6.65)μg/L vs(10.93±2.35)μg/L]、[(15.34±4.22)pmol/L vs(9.31±2.48)pmol/L]，萎缩性胃炎组、肠上皮化生组、低级别上皮内瘤变组PGⅠ、PGR降低，差异有统计学意义(P<0.05)。结论 血清PGⅠ、PGR、G-17可作为胃癌及其癌前病变筛查的指标。
关键词：胃癌;胃蛋白酶原;胃泌素-17;癌前病变
中图分类号：R735.2 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.22.060
文章编号：1006-1959(2019)22-0170-02
The Value of Pepsinogen and Gastrin-17 in the Screening of Gastric Precancerous Lesions
FANG Nian-fu，HE Qing-xia，YANG Wei-sheng，JIA Ke-hong，YUAN Guang-yong，YU Shu-yu
(Department of Gastroenterology，the Second People's Hospital of Jingdezhen，Jingdezhen 333000，Jiangxi，China)
Abstract：Objective To investigate the diagnostic value of serum pepsinogen Ⅰ， Ⅱ (PGⅠ， Ⅱ) and gastrin-17 (G-17) in precancerous lesions. Methods A retrospective analysis of 98 patients with digestive tract admitted to our hospital from January to October 2018 was performed. According to the results of gastroscopy and pathology， there were 32 patients with gastric ulcer， 21 patients with atrophic gastritis， and 25 patients with intestinal metaplasia. Twenty patients with low-grade intraepithelial neoplasia were enrolled， and 30 healthy subjects examined in our hospital were selected as the control group. Five groups of serum PGⅠ， PGⅡ pepsin ratio PGR， (PGⅠ/PGⅡ) and G-17 levels were compared by ELISA. Results Compared with the control group， PGⅠ， PGⅡ， and G-17 were elevated in the gastric ulcer group [(131.83±24.62) μg/L vs (95.29±23.47) μg/L]， [(15.31±6.65) μg/L vs (10.93± 2.35) μg/L]， [(15.34±4.22) pmol/L vs (9.31±2.48) pmol/L]， PGⅠ and PGR were decreased in atrophic gastritis group， intestinal metaplasia group and low-grade intraepithelial neoplasia group，the difference was statistically significant (P<0.05). Conclusion Serum PGⅠ， PGⅡ and G-17 can be used as indicators for screening gastric cancer and its precancerous lesions.
Key words：Gastric cancer;Pepsinogen;Gastrin-17;Precancerous lesions, 百拇医药(方年富，何庆霞，杨卫生，贾克红，袁光勇，余恕玉)
关键词：胃癌;胃蛋白酶原;胃泌素-17;癌前病变
中图分类号：R735.2 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.22.060
文章编号：1006-1959(2019)22-0170-02
The Value of Pepsinogen and Gastrin-17 in the Screening of Gastric Precancerous Lesions
FANG Nian-fu，HE Qing-xia，YANG Wei-sheng，JIA Ke-hong，YUAN Guang-yong，YU Shu-yu
(Department of Gastroenterology，the Second People's Hospital of Jingdezhen，Jingdezhen 333000，Jiangxi，China)
Abstract：Objective To investigate the diagnostic value of serum pepsinogen Ⅰ， Ⅱ (PGⅠ， Ⅱ) and gastrin-17 (G-17) in precancerous lesions. Methods A retrospective analysis of 98 patients with digestive tract admitted to our hospital from January to October 2018 was performed. According to the results of gastroscopy and pathology， there were 32 patients with gastric ulcer， 21 patients with atrophic gastritis， and 25 patients with intestinal metaplasia. Twenty patients with low-grade intraepithelial neoplasia were enrolled， and 30 healthy subjects examined in our hospital were selected as the control group. Five groups of serum PGⅠ， PGⅡ pepsin ratio PGR， (PGⅠ/PGⅡ) and G-17 levels were compared by ELISA. Results Compared with the control group， PGⅠ， PGⅡ， and G-17 were elevated in the gastric ulcer group [(131.83±24.62) μg/L vs (95.29±23.47) μg/L]， [(15.31±6.65) μg/L vs (10.93± 2.35) μg/L]， [(15.34±4.22) pmol/L vs (9.31±2.48) pmol/L]， PGⅠ and PGR were decreased in atrophic gastritis group， intestinal metaplasia group and low-grade intraepithelial neoplasia group，the difference was statistically significant (P<0.05). Conclusion Serum PGⅠ， PGⅡ and G-17 can be used as indicators for screening gastric cancer and its precancerous lesions.
Key words：Gastric cancer;Pepsinogen;Gastrin-17;Precancerous lesions, 百拇医药(方年富，何庆霞，杨卫生，贾克红，袁光勇，余恕玉)